Safety and Use of Polio Vaccines

HRD-87-83BR: Published: May 11, 1987. Publicly Released: May 11, 1987.

Additional Materials:


Office of Public Affairs
(202) 512-4800

Pursuant to a congressional request, GAO reviewed: (1) actions the federal government took to improve the safety of the oral polio vaccine (OPV); (2) the basis for recommending the use of a live polio vaccine for routine childhood immunization; and (3) the steps required to initiate an inactivated polio vaccine (IPV) for childhood immunization.

GAO found that: (1) federal research efforts to improve the safety of live polio vaccines were adequate; (2) FDA proposed changes to its OPV regulations and manufacturing requirements for future OPV licensed in the United States; and (3) the Immunization Practices Advisory Committee recommended the use of OPV because it could immunize unvaccinated people through contact and provide a higher level of intestinal immunity than IPV. GAO also found that the federal government would have to initiate several actions to recommend IPV for childhood immunization, specifically: (1) licensing a more potent IPV for marketing in the United States; (2) demonstrating the efficacy and safety of a more potent IPV; and (3) reducing the importation of polio viruses into the United States.

Oct 4, 2017

Oct 3, 2017

Sep 29, 2017

Sep 13, 2017

Sep 12, 2017

Sep 8, 2017

Sep 7, 2017

Looking for more? Browse all our products here